OLEMA PHARMACEUTICALS, INC. Investing Cash Flow
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Investing Cash Flow of $45.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $40.84M, a 19.30% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $4.53M.
- OLEMA PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$162.18M.
- OLEMA PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $17.27M, a 62.38% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$155.76M.
- OLEMA PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$93.53M.
- OLEMA PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$4.85M, a 105.30% decline from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2022 was $91.48M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $40.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $45.37M 10-Q · filed 2026-08-10 | -$116.81M derived: sum of 3 quarters · filed 2026-08-10 | -$99.54M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $4.53M 10-Q · filed 2026-05-12 | -$157.66M derived: sum of 2 quarters · filed 2026-05-12 | -$140.38M derived: sum of 3 quarters · filed 2026-05-12 | -$106.15M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$162.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$144.91M derived: sum of 2 quarters · filed 2026-03-16 | -$110.68M derived: sum of 3 quarters · filed 2026-08-10 | -$155.76M 10-K · filed 2026-03-16 |
| 2025-09-30 | $17.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $51.51M derived: sum of 2 quarters · filed 2026-08-10 | $6.42M 10-Q · filed 2025-11-10 | -$108.00M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $34.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$10.85M 10-Q · filed 2026-08-10 | -$125.27M derived: sum of 3 quarters · filed 2026-08-10 | -$79.35M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$45.08M 10-Q · filed 2026-05-12 | -$159.51M derived: sum of 2 quarters · filed 2026-05-12 | -$113.59M derived: sum of 3 quarters · filed 2026-05-12 | -$118.47M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$114.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$68.50M derived: sum of 2 quarters · filed 2026-03-16 | -$73.38M derived: sum of 3 quarters · filed 2026-03-16 | -$93.53M 10-K · filed 2026-03-16 |
| 2024-09-30 | $45.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $41.04M derived: sum of 2 quarters · filed 2025-11-10 | $20.90M 10-Q · filed 2025-11-10 | -$10.02M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$4.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$25.02M 10-Q · filed 2025-08-11 | -$55.94M derived: sum of 3 quarters · filed 2025-08-11 | -$81.37M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$20.14M 10-Q · filed 2025-05-13 | -$51.06M derived: sum of 2 quarters · filed 2025-05-13 | -$76.50M derived: sum of 3 quarters · filed 2025-05-13 | -$62.38M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$30.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$56.35M derived: sum of 2 quarters · filed 2025-03-18 | -$42.24M derived: sum of 3 quarters · filed 2025-03-18 | -$4.85M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$25.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$11.32M derived: sum of 2 quarters · filed 2024-11-12 | $26.06M 10-Q · filed 2024-11-12 | $42.40M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $14.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $51.50M 10-Q · filed 2024-08-06 | $67.84M derived: sum of 3 quarters · filed 2024-08-06 | $88.00M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $37.39M 10-Q · filed 2024-05-08 | $53.72M derived: sum of 2 quarters · filed 2024-05-08 | $73.89M derived: sum of 3 quarters · filed 2024-05-08 | $103.30M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $16.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $36.50M derived: sum of 2 quarters · filed 2024-03-11 | $65.91M derived: sum of 3 quarters · filed 2024-03-11 | $91.48M 10-K · filed 2024-03-11 |
| 2022-09-30 | $20.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $49.58M derived: sum of 2 quarters · filed 2023-11-07 | $75.14M 10-Q · filed 2023-11-07 | $81.14M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $29.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $54.98M 10-Q · filed 2023-08-08 | $60.98M derived: sum of 3 quarters · filed 2023-08-08 | $48.20M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $25.57M 10-Q · filed 2023-05-09 | $31.57M derived: sum of 2 quarters · filed 2023-05-09 | $18.78M derived: sum of 3 quarters · filed 2023-05-09 | $29.71M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$6.78M derived: sum of 2 quarters · filed 2023-03-09 | $4.15M derived: sum of 3 quarters · filed 2023-03-09 | -$275.44M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$12.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$1.85M derived: sum of 2 quarters · filed 2022-11-08 | -$281.44M 10-Q · filed 2022-11-08 | -$281.49M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $10.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$268.65M 10-Q · filed 2022-08-09 | -$268.70M derived: sum of 3 quarters · filed 2022-08-09 | -$268.69M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$279.58M 10-Q · filed 2022-05-09 | -$279.63M derived: sum of 2 quarters · filed 2022-05-09 | -$279.63M derived: sum of 3 quarters · filed 2022-05-09 | -$279.63M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$41.00K derived: sum of 2 quarters · filed 2022-02-28 | -$47.00K derived: sum of 3 quarters · filed 2022-02-28 | -$56.00K 10-K · filed 2022-02-28 |
| 2020-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $4.00K derived: sum of 2 quarters · filed 2021-11-10 | -$5.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$15.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$9.00K 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |